Needham raised the firm’s price target on Revolution Medicines to $62 from $46 and keeps a Buy rating on the shares. The analyst cites the updated data for RMC-6236 in second-line pancreatic ductal adenocarcinoma announced by the company at a conference call yesterday, as it “supported a superior profile”. Revolution’s clinical data in RAS mutant patients was also disclosed for the first time, suggesting an efficacy similar to KRAS G12X, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Balances 2024 Loss Projection with Promising Cancer Drug Trials
- Tesla downgraded, Booking Holdings upgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Overweight at Barclays
- Revolution reports publication showing anti-tumor activity of RAS(ON) inhibitors
- Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer